GSK's darapladib misses in Phase III CHD trial

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) said once-daily oral darapladib ( SB-480848) plus standard of care (SOC) missed the primary endpoint vs. placebo plus SOC in the Phase III STABILITY trial to treat chronic coronary heart disease (CHD). Darapladib plus SOC -- which could include a statin, aspirin and blood pressure medications -- did not improve time to the first occurrence of any component of the composite of major adverse cardiovascular events (MACE) consisting of cardiovascular death, non-fatal myocardial infarction (MI) and non-fatal stroke vs. placebo plus SOC (relative risk reduction of 6%, p=0.199). The double-blind, international trial enrolled over 15,000 patients with chronic CHD. ...